Site Search
The Latest on H5 Avian Influenza: Bill Morice, M.D., Ph.D. - Insights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss...
Guidance on subtyping of influenza A test results - Insights
Mayo Clinic Laboratories’ guidance for subtyping influenza A in response to a CDC advisory for hospitalized patients
Malabsorption panel: Filling a gap in pediatric care - Insights
Mayo Clinic Laboratories is committed to innovation that provides the right test at the right time for the right patients. That effort always starts with identifying gaps in patient care. Filling those gaps sometimes involves not developing...
A novel testing approach for newly identified VEXAS syndrome - Insights
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome —...
Cross-laboratory collaboration accelerates gold-standard SRA testing - Insights
Utilizing testing capabilities of two separate laboratory facilities, Mayo Clinic Laboratories’ new serotonin release assay (SRA) is a gold-standard test supported by decades of clinical hematopathologic experience and advanced mass...
COVID-19: The pandemic that's forever changed laboratory testing - Insights
Since March 2020, the COVID-19 pandemic has had a lasting impact on the lives of millions of people around the world, including the many brave health care workers who risked their own health to provide lifesaving care to those infected by...
Lab discoveries fuel updates for autoimmune movement disorders test - Insights
Mayo Clinic Laboratories expanded movement disorders panel better identifies autoimmune conditions. Four recently identified biomarkers — septin-5, septin-7, neurochondrin, and adaptor protein-3B2 — have been added to the panel, and all...
Mayo Clinic’s cardiac (CV) remote monitoring service uses the compact MoMe Kardia cardiac monitoring device that yields a continuous, 24/7 stream of a patient’s ECG and motion data, no matter their location. Any troubling or burgeoning...
Progressive alliance advances science through patient-powered research - Insights
Tying together the expertise and curiosity of Mayo Clinic autoimmune neurology researchers with eager patients who have rare disease and are looking for answers, the innovative collaboration benefits both patients affected by MOGAD and...
Multiomics: A new model for identifying biomarkers to predict severe COVID-19 outcomes - Insights
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team...
Phage immunoprecipitation sequencing identifies previously unknown disease biomarkers - Insights
In Mayo Clinic’s Advanced Diagnostics Laboratory, there are dozens of projects underway at once to develop new technologies, discover novel findings, validate new tests, and support physicians in providing advanced patient care. For...
Rapidly progressive dementia - Insights
Mayo Clinic Laboratories’ first-in-class testing for rapidly progressive dementia and Creutzfeldt-Jakob disease uses a sensitive and specific seed amplification assay that detects and identifies prion proteins in CSF alongside a clinically...
Mayo Clinic Laboratories’ comprehensive menu of genetic cardiovascular testing provides results that support gene-based strategies to manage inherited cardiovascular disease.
Gynecological cancer - Insights
Find out how our gynecological cancer panels evaluate genes with relevance to diagnosing and treating uterine, ovarian, and endometrial cancers.
Mayo Clinic Laboratory and Pathology Research Roundup: May 14 - Insights
This week's research roundup feature: Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPNs) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies,...
Mayo Clinic Laboratory and Pathology Research Roundup: May 21 - Insights
This week's research roundup feature: Monoclonal immunoglobulin (MIg) crystalline nephropathies are rare lesions resulting from precipitation of MIgs in the kidney as crystalline inclusions. They can be categorized into lesions with...
Nonalcoholic Steatohepatitis (NASH)-FibroTest* [Test in Focus] - Insights
Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical...
Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D. - Insights
Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.
Mayo Clinic Laboratories offers a robust menu of biomarker testing to assess liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Hepatocellular carcinoma - Insights
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be effectively treated in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and...
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...
Viral Hepatitis Testing - Mayo Clinic Laboratories
At Mayo Clinic, we utilize an algorithmic approach to testing that takes the guesswork out of test ordering to focus on proper test utilization, saving your institution time and money.
Diagnostic Guidelines for Celiac Disease - Insights
In this "Hot Topic," Melissa Snyder, Ph.D., provides a brief review of published guidelines for the diagnosis of celiac disease, with a specific focus on the role of laboratory testing.
Diagnostic Testing Algorithms for Celiac Disease - Insights
In this month’s “Hot Topic,” Melissa Snyder, Ph.D., will review the diagnostic testing algorithms for celiac disease and highlight the advantages and limitations of certain tests, including serology and genetic assays.
Diagnostic Testing Algorithms for Celiac Disease - Insights
In this month's "Hot Topic," Melissa Snyder, Ph.D., co-director of the antibody immunology laboratory at Mayo Clinic, discusses celiac disease and the role of diagnostic testing algorithms.
Mayo Clinic Classical Hematology Conference - Insights
This conference will provide reviews and updates about the laboratory and clinical aspects of nonmalignant hematology and bleeding and thrombotic disorders. Combining the clinical and laboratory experience of Mayo Clinic faculty, we will...
Hereditary movement disorders - Insights
Learn about our advanced genetic testing for hereditary movement disorders, including ataxias, Huntington’s disease, and Parkinson’s disease.
Neurodevelopmental disorders - Insights
Learn more about how chromosomal microarray can be used as a first-tier diagnostic test for those with congenital abnormalities and developmental disabilities.
Sleep Disorder Testing - Mayo Clinic Laboratories
Determining orexin-A/ hypocretin-1 levels through CSF testing provides a sensitive and specific result to guide appropriate treatment for patients.
Chromosomal microarray - Insights
Learn how our microarray evaluations identify, analyze, and assess clinically significant chromosomal abnormalities.
Hereditary neuromuscular disorders - Insights
Find out how our distinctive approach to evaluating for inherited neuromuscular disorders uses phenotypic information to streamline diagnosis.
Whole genome sequencing - Insights
Check out Mayo Clinic Laboratories’ whole genome testing, a next-generation sequencing assay that interrogates nearly every base pair of an individual’s DNA, including the mitochondrial genome.
Mitochondrial disease - Insights
Learn about our four molecular testing options, which can be used to confirm a diagnosis and identify a specific mitochondrial syndrome.
Hereditary hearing loss - Insights
Learn how our hereditary hearing loss test can help avoid unnecessary workups and appointments and reduce anxiety for patients and their families.
Pediatric CNS Disorder Testing - Mayo Clinic Laboratories
We offer a first-of-its-kind profile including only the antibodies that are pertinent to pediatric CNS disorders—all in one evaluation.
Hereditary epilepsy - Insights
Find out how we perform in-depth mutation and copy number variant analysis to determine causes of epilepsy and identify potential treatment options.
Whole exome sequencing - Insights
Learn more about how whole exome sequencing at Mayo Clinic Laboratories can quickly end diagnostic testing odysseys for patients with suspected genetic disorders.
Frozen sections: Value & challenges - Insights
In this episode of Lab Medicine Rounds, Rondell Graham, M.B.B.S., associate professor of Laboratory Medicine and Pathology at Mayo Clinic, discusses the value and challenges of frozen sections.
Sustainable bridges: Lab medicine & cardiology - Insights
In this episode, Jeffrey (Jeff) Meeusen, Ph.D., assistant professor of Laboratory Medicine and Pathology and clinical chemist in the Division of Clinical Core Laboratory Services at Mayo Clinic, discusses the interface between...
Cardiovascular laboratory: Biomarkers, testing, & clinical implications - Insights
In this episode, Vlad Vasile, M.D., Ph.D., assistant professor of Laboratory Medicine and Pathology and cardiologist at Mayo Clinic, discusses cardiovascular risk testing, including biomarkers and clinical implications.
Newborn Screen Follow-up for Severe Combined Immunodeficiency Syndrome (SCID) [Algorithm] - Insights
The algorithm can be viewed here.
The Metabolic Autopsy: Postmortem Screening in Cases of Sudden, Unexpected Death - Insights
In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.
Featuring a full menu of advanced sequencing assays, Mayo Clinic Laboratories’ genetic test offerings for early-onset gastrointestinal disorders can provide diagnostic clarity that enables customized care.
For children who require thiopurine medications (such as azathioprine and 6-mercaptopurine) to treat inflammatory bowel disease (IBD), understanding how thiopurines are metabolized is vital to choosing the most effective treatment. Because...
A worldwide increase of the incidence of early-onset pediatric inflammatory bowel disease means more children than ever are diagnosed and treated for life-altering IBD diagnoses. However, not all children suspected of early-onset IBD have...
Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
TPMT Testing in Treatment of Inflammatory Bowel Disease [Test in Focus] - Insights
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
Biologic Therapies: Reflexive Approaches to Optimizing Treatment for IBD - Insights
Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased...